The information leaflet for the following product is now available in eLeaflet format:
Statins and warfarin shown to share mechanism that causes CVD, Diabetes
OSLO, NORGE and METUCHEN, NJ (23 June 2016) – A new review paper published in leading journal, Pharmacology, examines the positive associations observed between cardiovascular disease (CVD) and type 2 diabetes mellitus (DM), and the negative effect of medications prescribed to both groups of patients share a common mechanism: to inhibit vitamin K2-dependent processes, which was interpreted to lead to increased onset of CVD, DM, chronic kidney disease, bone fracture, and even mental disorder.
The authors of the review paper1, “Medicines and Vegetable Oils as Hidden Causes of Cardiovascular Disease and Diabetes,” note that impaired vitamin K2-dependent processes by some types of vegetable oils and medicines, but not plasma high low-density lipoprotein cholesterol, were proposed as the cause of CVD, DM and other lifestyle-related diseases.
“Once again the scientific community recognizes that the inhibition of vitamin K2 synthesis by common medications carries serious, newly recognized repurcussions,” says Hogne Vik, chief medical officer with NattoPharma, the world leader in vitamin K2 research and development, adding that while it has been well known for some time that statins inhibit CoQ10, a 2015 review paper2 finally highlighted that statins also inhibit K2 synthesis. ”Recognized Vitamin K2 antagonists significantly inhibit Vitamin K activity outside the liver with serious, unintended consequences.”
The function of K vitamins is unique among other vitamins and important throughout all life stages. Vitamin K2 activates proteins that are made in different organs in the body – clotting factors in the liver, osteocalcin in bones, and Matrix Gla Protein (MGP) in the vasculature. These proteins help coagulate blood, bind calcium to the surface of bones, and keep calcium from depositing in the arteries and soft tissues.
While the function of Vitamin K2 is vital to ensuring that the body properly utilizes calcium, studies have shown that 97 percent of Western populations are Vitamin K2 deficient/insufficient.3
“We are not only finally seeing recognition that Vitamin K2 is woefully insufficient in the diet, but the is a growing body of evidence that pharmaceuticals further exacerbate the problem of our limited Vitamin K2 status, delivering potentially dangerous consequences for human health,” Vik continues.
# # #
MenaQ7® is the best documented, commercially available vitamin K2 as MK-7 with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. MenaQ7® is available in two varieties: natural vitamin K2 as MK-7 Crystals and nature-identical synthetic vitamin K2 as MK-7 PURE. For more information on the health benefits of MenaQ7, visit menaq7.com.
NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, and has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPahrma USA, Inc., in Meuchen, NJ. For more information, visit nattopharma.com.
1 Okuyama H et al. Medicines and Vegetable Oils as Hidden Causes of Cardiovascular Disease and Diabetes. Pharmacology 2016;98:134–170. DOI: 10.1159/000446704.
2 Okuyama H et al. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Rev Clin Pharmacol. 2015 Mar;8(2):189-99. doi: 10.1586/17512433.2015.1011125. Epub 2015 Feb 6.
3 Shea MK et al. Circulating uncarboxylated matrix gla protein is associated with vitamin K nutritional status, but not coronary artery calcium, in older adults. J Nutr. 2011 Aug;141(8):1529‐34.
myHealthbox presenterà le sue soluzioni innovative di eLeaflet al Pharmintech di Bologna dal 13 al 15 Aprile 2016.
Tramite il nuovo display interattivo della Corepixx sarà possibile provare dal vivo tutte le nuove funzionalità della nostra offerta eLeaflet.
Vieni a trovarci al Padiglione 22 Stand B88
myHealthbox will be presenting its eLeaflet solution at Pharmintech in Bologna from the 13th to the 15th of April 2016.
You will be able to try out most of our services live through a new interactive screen provided by Corepixx.
Come meet us at Area 22 Stand B88
It is now common in our society that different ethnic groups and languages meet and coexist in the same country, in Italy alone there are now more than 5 million people that speak a primary language that is different from Italian (Romanian, Albanian and Arabic are amongst the most spoken). To these language minorities we can then add turists and travellers that live in Italy and speak one of the main European languages (English, Spanish and German are the main ones).
It is easy to see how, when the is a need to read information about the use of medicines of healthcare products (for example the dosage) these people would prefer reading information in their native language which they consider “safer” as less subject to interpretation errors.
Moreover there are in the world dozens of situations where 2 or more official languages are present in the same country (i.e. German in the Alto Adige region in Italy or French and Dutch in Belgium).
In Italy for example there is a requirement, for product sold in the Alto Adige region, for providing patient information in Italian and in German; until recently compliance was achieved by providing two printed versions of the patient information leaflet inside the packaging,today an alternative solution is available by making available a digital versions of the leaflet in German language via web or mobile, these can be also easily printed in the pharmacy upon request.
The use of myHealthbox as the digital leaflets distribution platform, the data security solutions implemented (both at leaflet and platform level) and the possibility of providing this information also via a QR code printed on the packaging make myHealthbox the solution of choice for those companies that need to satisfy government requirements for selling healthcare product in bi- or multi-lingual regions like Alto Adige in Italy.
Oggi più che mai viviamo in una realtà dove diverse etnie e lingue si incontrano e convivono nello stesso paese, solo in Italia si contano più di 5 milioni di persone che non hanno l’italiano come lingua principale (Romeno, Albanese e Arabo sono le lingue principali) oltre naturalmente a turisti e persone che sono presenti in Italia per lavoro e che parlano una delle altre lingue Europee (Inglese, Spagnolo e tedesco sono le principali).
Si può facilmente capire come, quando si tratta di leggere informazioni sull’uso di medicinali o prodotti per la salute (ad es. la posologia di una farmaco), queste persone preferiscano usare la propria lingua nativa che ritengono istintivamente più “sicura” e meno soggetta ad errori di interpretazione.
Ci sono poi nel mondo decine di realtà dove 2 o più lingue ufficiali coesistono all’interno dello stesso paese (come ad esempio la lingua Tedesca in Alto Adige o Francese ed Olandese in Belgio).
In Italia esiste l’obbligo, per i farmaci venduti in Alto Adige, di fornire le informazioni per il paziente sia in Italiano che in Tedesco; fino a poco tempo fa esistevano 2 versioni cartacee del foglio illustrativo, oggi è possibile utilizzare versioni digitali del foglio in Tedesco disponibili sia tramite web e mobile che stampabili in farmacia su richiesta.
La distribuzione dei fogli illustrativi digitali attraverso la piattaforma myHealthbox, le soluzioni di sicurezza dei dati implementate (sia a livello di formato che di piattaforma) e la possibilità di accedere a queste informazioni anche tramite un QR code sulla confezione permettono di ottemperare a tutti i requisiti stabiliti dal Ministero della Salute e da AIFA in termini di soluzioni per il bilinguismo sia specificatamente per la regione Alto Adige che per altre regioni.